The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy
JOURNAL OF BUON, cilt.25, sa.1, ss.268-273, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 1
- Basım Tarihi: 2020
- Dergi Adı: JOURNAL OF BUON
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.268-273
- Anahtar Kelimeler: lung cancer, NSCLC, immunotherapy, PD-1, PD-L1, DEATH-LIGAND 1, PROGNOSTIC-FACTOR, PULMONARY ADENOCARCINOMA, CLINICAL-SIGNIFICANCE, PROTEIN EXPRESSION, DOCETAXEL, STATISTICS, MUTATIONS, NIVOLUMAB
- Gazi Üniversitesi Adresli: Evet
Özet
Purpose: There are conflicting results in the literature about the relationship between PD-1/PD-L1 expression and prognosis in non-small cell lung cancer (NSCLC). The purpose of this study was to identify the relationship between NSCLC patients' clinicopathologic characteristics and PD-1/PD-L1 expression.